Peptide Therapeutics For The Treatment Of Autoimmune Diseases: Stability, Delivery And Disposition
Funder
National Health and Medical Research Council
Funding Amount
$368,467.00
Summary
Autoimmune diseases affect around 120 million people worldwide. This project will progress the development of a peptide that suppresses disease-causing autoantigen-specific immune responses without affecting protective responses. Different routes of delivery for this peptide will be evaluated, as well as slow-release formulations that will extend its in vivo lifetime. The outcome will be a patient-friendly form of this therapeutic lead that can be taken forward to preclinical evaluation.
Anti-inflammatory Compound Development For The Treatment Of Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$674,659.00
Summary
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent and rapidly growing heart condition with no proven effective therapies. We will develop novel drugs to treat HFpEF by focussing on heart scarring and inflammation. We have promising drug candidates that will be developed during the project, and these will be ready for for phase I clinical trial by the end of this grant. The outcome of this study is poised to address the significant unmet medical need.
Lipopeptide Antibiotics For XDR Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$994,897.00
Summary
The polymyxins are a drug class considered to be a last-resort treatment option for multidrug-resistant (MDR) and extremely drug resistant (XDR) Gram-negative infections. Unfortunately resistance is rapidly developing against these antibiotics, leaving no effective therapies and resulting in patient death. This project aims to develop an antibiotic with superior spectra of action and improved safety profiles compared to the polymyxins, with activity against polymyxin-resistant bacteria.
Novel Membrane-targeted Antibiotics Against Drug-resistant Gram-positive Bacterial Infections
Funder
National Health and Medical Research Council
Funding Amount
$1,351,496.00
Summary
This project aims to develop a best in class antibiotic, Vancapticin, with superior efficacy, broader spectra of action and improved therapeutic index than existing therapies for Gram-positive (G+ve) bacterial infections. The research team has identified lead candidates that offer equivalent &/or superior potency, efficacy & pharmacokinetic profiles compared to several clinical comparators. NHMRC Development funding is required to select a candidate for an Investigative New Drug application.
Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation To Improve Antibody Drug Conjugate Production And Performance
Funder
National Health and Medical Research Council
Funding Amount
$402,046.00
Summary
Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.